你好!欢迎访问 登录|立即注册

0576-88813233

|
当前位置:科瑞产品

ND-630

ND-630 1434635-54-7
规格 价格 库存 数量
在线咨询 大包装询价 加入购物车
如您需要更多数量的报价,请点击立即获取报价或者通过电子邮件sales@crene.cn把您需要的数量信息提交给我们我们会在第一时间回复您,谢谢!
产品信息
产品名称:ND-630 纯度:98%min
CAS NO:1434635-54-7 溶解度:Soluble in DMSO
分子式:C28H31N3O8S 包装:可按客户要求包装。
分子量:569.63 贮存:Store at -20℃ 3 years
质量控制
备注说明
ND-630 is an acetyl-CoA carboxylase (ACC) inhibitor; inhibits human ACC1 and ACC2 with IC50 values of 2.1 and 6.1 nM, respectively.ND-630 inhibits hACC1 (IC50=2.1±0.2 nM) and hACC2 (IC50=6.1±0.8 nM). Inhibition is reversible and highly specific for ACC. ND-630 inhibits ACC activity by interacting within the phosphopeptide-acceptor and dimerization site of the enzyme to prevent dimerization. ND-630 inhibits fatty acid synthesis with an EC50 of 66 nM in HepG2 cells without altering the total cell number, cellular protein concentration, and incorporation of acetate into cholesterol[1].Chronical administration of ND-630 to rats with diet-induced obesity reduces hepatic steatosis, improves insulin sensitivity, reduces weight gain without affecting food intake, and favorably affects dyslipidemia. Chronical administration of ND-630 Zucker diabetic fatty rats, ND-630 reduces hepatic steatosis, improves glucose-stimulated insulin secretion, and reduces hemoglobin A1c (0.9% reduction). ND-630 exhibits an aqueous solubility of 594 μM and human and rat plasma protein binding of 98.5% and 98.6%, respectively. Pharmacokinetic evaluation of ND-630 in male Sprague–Dawley rats [i.v. 3 mg/kg; orally (p.o.) 10 mg/kg] yields a plasma t1/2 of 4.5 h, bioavailability of 37%, clearance of 33 mL/min/kg, volume of distribution of 1.9 L/kg, oral time of maximum plasma concentration of 0.25 h[1].

版权所有 Copyright(C) 2018-2021 台州市科瑞生物技术有限公司

技术支持:kerui  浙ICP备09021343号
公司所列产品中涉及到专利,只供研发使用,不做销售;管制产品将严格遵守中国法律和购买客户国法律的规定销售,所有产品都不适用于人用 如被销售到构成专利侵权的国家,则相应的一切风险将由买方承担。